特应性皮炎系统治疗的最新进展。

IF 3.2 Q1 PEDIATRICS

Clinical and Experimental Pediatrics Pub Date : 2024-11-01 DOI:10.3345/cep.2024.00339

Jiyoung Ahn

{"title":"特应性皮炎系统治疗的最新进展。","authors":"Jiyoung Ahn","doi":"10.3345/cep.2024.00339","DOIUrl":null,"url":null,"abstract":"Atopic dermatitis (AD) is a complex disease with multifactorial pathogenesis and variable clinical presentation. Up to one-fifth of patients with AD develop moderate to severe disease that is often refractory to classical therapies and can compromise quality of life. This review summarizes recent clinical evidence on biological agents and small-molecule immunotherapies for the treatment of AD.","PeriodicalId":36018,"journal":{"name":"Clinical and Experimental Pediatrics","volume":"67 11","pages":"580-588"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551601/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recent updates on systemic treatment of atopic dermatitis.\",\"authors\":\"Jiyoung Ahn\",\"doi\":\"10.3345/cep.2024.00339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atopic dermatitis (AD) is a complex disease with multifactorial pathogenesis and variable clinical presentation. Up to one-fifth of patients with AD develop moderate to severe disease that is often refractory to classical therapies and can compromise quality of life. This review summarizes recent clinical evidence on biological agents and small-molecule immunotherapies for the treatment of AD.\",\"PeriodicalId\":36018,\"journal\":{\"name\":\"Clinical and Experimental Pediatrics\",\"volume\":\"67 11\",\"pages\":\"580-588\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551601/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Pediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3345/cep.2024.00339\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3345/cep.2024.00339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

摘要

特应性皮炎（AD）是一种复杂的疾病，具有多因素致病机理和多变的临床表现。多达五分之一的特应性皮炎患者会出现中度至重度疾病，通常对传统疗法难治，并会影响生活质量。本综述总结了治疗AD的生物制剂和小分子免疫疗法的最新临床证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Recent updates on systemic treatment of atopic dermatitis.

Atopic dermatitis (AD) is a complex disease with multifactorial pathogenesis and variable clinical presentation. Up to one-fifth of patients with AD develop moderate to severe disease that is often refractory to classical therapies and can compromise quality of life. This review summarizes recent clinical evidence on biological agents and small-molecule immunotherapies for the treatment of AD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Experimental Pediatrics Nursing-Pediatrics

CiteScore

8.00

自引率

2.40%

发文量

审稿时长

60 weeks